Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Fulgent Genetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Fulgent Genetics's regulatory disclosures and financial reporting.
Fulgent Genetics reported second quarter 2026 results with revenue of $85.4 million, up from $81.8 million a year earlier, and a GAAP net loss of $29.5 million, or $(1.05) per share. GAAP gross margin was 30.1%, non-GAAP gross margin 31.3%, and non-GAAP net loss $16.2 million.
The company repurchased approximately 1.5 million shares for $23.8 million in the quarter and ended with $551.5 million in cash, cash equivalents, restricted cash and marketable securities, excluding an anticipated $106.1 million tax refund. For 2026, management guides revenue to $330–$340 million, non-GAAP loss of $63–$67 million, non-GAAP loss per share of $2.22–$2.35 and year-end cash of about $610 million. Management linked the guidance revision to processing delays during the final phase of its billing and revenue cycle transition that affected collection rates.
In its therapeutics segment, Fulgent highlighted Phase 2 data for FID‑007 in recurrent/metastatic head and neck cancer, with an objective response rate of 61.9%, one-year overall survival of 63.4%, a manageable safety profile, and plans to advance to a Phase 3 study.
Fulgent Genetics, Inc. reports that CFO and Treasurer Paul Kim had 2,747 shares of common stock withheld on July 26, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units assumed in a 2022 merger. After this tax withholding disposition, he directly owns 359,798 shares.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax‑withholding disposition of 4,361 shares of common stock on July 26, 2026, at $19.67 per share, to cover taxes from vesting restricted stock units. After this, he directly held 363,244 shares, with an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. (FLGT) reports that Chief Scientific Officer Hanlin Gao had 1,645 shares of Common Stock withheld on July 26, 2026 to satisfy tax withholding obligations from the vesting of restricted stock units assumed in a prior merger, leaving him with 988,729 shares directly held.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 2,146 shares of common stock at a weighted-average price of $17.8855 per share on June 2, 2026. According to the disclosure, the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025.
Following the sale, Xie holds 367,605 shares of Fulgent Genetics common stock directly and an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine share disposition related to tax withholding. On June 1, 2026, 2,087 shares of common stock were withheld at $18.09 per share to satisfy tax obligations triggered by the vesting of restricted stock units granted on February 25, 2025. After this withholding, Kim directly holds 362,545 shares of Fulgent Genetics common stock, indicating the transaction was a small, non-market event tied to compensation rather than an open-market sale.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of 1,688 shares of common stock at a weighted-average price of $17.8855 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Gao directly holds 990,374 shares of Fulgent Genetics common stock.
Fulgent Genetics CEO Ming Hsieh reported a Form 4 showing shares withheld for taxes on vested stock awards, not an open‑market trade. On June 1, 2026, 4,392 shares of common stock were disposed of at $18.09 per share to satisfy tax withholding obligations from restricted stock units granted on February 25, 2025.
After this tax-withholding disposition, Hsieh directly holds 893,293 common shares. He also has substantial indirect holdings through family and trust structures, including shares held by the Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member residing in the same household.
Fulgent Genetics filed a Form 144 notice reporting intended resale of restricted common stock that vested on 02/25/2025. The filing lists 45,304 shares linked to equity compensation and discloses a prior sale of 1,201 shares on 05/27/2026.
The notice names Jian Xie and gives broker information for Morgan Stanley Smith Barney LLC. The filing is administrative: it reports quantities and dates related to restricted stock and a recent small disposition.